{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:47:40Z","timestamp":1792784860487,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shanghai Golden Leaf Med Tech (Brattea) Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Sympathetic hyperactivity is crucial driving factor for hyperglycemia in type 2 diabetes (T2D). We conducted a multicenter, open-label, single-arm trial to evaluate the safety and efficacy of endovascular denervation (EDN) targeting the celiac and hepatic arteries in patients with poorly controlled T2D, defined as glycated hemoglobin (HbA1c)\u2009&gt;\u20097.5% and &lt;10.5% despite treatment with metformin and at least one other antidiabetic agent (registered with the National Medical Products Administration of China and ClinicalTrials.gov, NCT05631561). A total of 37 patients were enrolled across three centers, and 30 patients underwent EDN between December 2022 and October 2023. Follow-up visits were conducted at 1, 3, 6, and 12 months. The primary endpoints were device- and\/or procedure-related major adverse events (MAEs) within 30 days post-procedure and changes in HbA1c at 6 months. In treated patients, the baseline mean HbA1c was 9.0%, and the baseline mean fasting plasma glucose was 8.6\u2009mmol\/L. No MAEs were observed within 30 days. HbA1c decreased by 1.0% at 6 months (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001), with reductions of 1.0%, 1.2%, and 0.9% at 1, 3, and 12 months post-EDN, respectively. Time in range (3.9\u201310.0\u2009mmol\/L) increased by 15.4%, 14.9%, 7.6% and 11.7% at each follow-up time point. Blood pressure also showed reductions during follow-up. Adverse events were reported in 11 (37%) patients, with mild to moderate gastrointestinal symptoms being the most common. These exploratory findings provide a rationale for further evaluating the efficacy of EDN in improving glycemic control in T2D patients through randomized controlled trials.\n                  <\/jats:p>","DOI":"10.1038\/s41392-025-02459-6","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T05:25:58Z","timestamp":1763011558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Catheter-based endovascular celiac and hepatic denervation for type 2 diabetes: a multicenter, open-label, single-arm study"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5056-2242","authenticated-orcid":false,"given":"Zhi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifu","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dechen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3267-9292","authenticated-orcid":false,"given":"Jiajun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0083-6978","authenticated-orcid":false,"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7889-1697","authenticated-orcid":false,"given":"Jianping","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao-Jun","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"2459_CR1","doi-asserted-by":"crossref","unstructured":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402, 203\u2013234 (2023).","DOI":"10.1016\/S0140-6736(23)01301-6"},{"key":"2459_CR2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng, Z. et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct. Target Ther. 9, 234 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2459_CR3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas, J. P. et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N. Engl. J. Med. 385, 503\u2013515 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2459_CR4","doi-asserted-by":"publisher","first-page":"e000761","DOI":"10.1136\/bmjdrc-2019-000761","volume":"7","author":"S Patel","year":"2019","unstructured":"Patel, S. et al. Effect of medication adherence on clinical outcomes in type 2 diabetes: analysis of the SIMPLE study. BMJ Open Diabetes Res. Care 7, e000761 (2019).","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"2459_CR5","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.2337\/dci24-0035","volume":"47","author":"ZI Saeed","year":"2024","unstructured":"Saeed, Z. I., Ostrominski, J. W. & Aroda, V. R. Polypharmacy in type 2 diabetes: appropriate or cause for concern?. Diabetes Care 47, 2104\u20132106 (2024).","journal-title":"Diabetes Care"},{"key":"2459_CR6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S2213-8587(14)70033-6","volume":"3","author":"M Schlaich","year":"2015","unstructured":"Schlaich, M., Straznicky, N., Lambert, E. & Lambert, G. Metabolic syndrome: a sympathetic disease?. Lancet Diabetes Endocrinol. 3, 148\u2013157 (2015).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2459_CR7","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1097\/HJH.0000000000002431","volume":"38","author":"G Grassi","year":"2020","unstructured":"Grassi, G. et al. Sympathetic neural abnormalities in type 1 and type 2 diabetes: a systematic review and meta-analysis. J. Hypertens. 38, 1436\u20131442 (2020).","journal-title":"J. Hypertens."},{"key":"2459_CR8","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1161\/HYPERTENSIONAHA.122.20503","volume":"80","author":"A Biffi","year":"2023","unstructured":"Biffi, A. et al. Effects of renal denervation on sympathetic nerve traffic and correlates in drug-resistant and uncontrolled hypertension: a systematic review and meta-analysis. Hypertension 80, 659\u2013667 (2023).","journal-title":"Hypertension"},{"key":"2459_CR9","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.2337\/db16-0205","volume":"65","author":"AK Miroslawska","year":"2016","unstructured":"Miroslawska, A. K. et al. Renal denervation for resistant hypertension fails to improve insulin resistance as assessed by hyperinsulinemic-euglycemic step clamp. Diabetes 65, 2164\u20132168 (2016).","journal-title":"Diabetes"},{"key":"2459_CR10","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.2337\/db16-0698","volume":"65","author":"MS Iyer","year":"2016","unstructured":"Iyer, M. S. et al. Renal denervation reverses hepatic insulin resistance induced by high-fat diet. Diabetes 65, 3453\u20133463 (2016).","journal-title":"Diabetes"},{"key":"2459_CR11","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41569-020-0364-1","volume":"17","author":"L Lauder","year":"2020","unstructured":"Lauder, L., Azizi, M., Kirtane, A. J., B\u00f6hm, M. & Mahfoud, F. Device-based therapies for arterial hypertension. Nat. Rev. Cardiol. 17, 614\u2013628 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"2459_CR12","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(22)01787-1","volume":"400","author":"DL Bhatt","year":"2022","unstructured":"Bhatt, D. L. et al. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet 400, 1405\u20131416 (2022).","journal-title":"Lancet"},{"key":"2459_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00592-023-02208-7","volume":"61","author":"E Koutra","year":"2024","unstructured":"Koutra, E. et al. Unravelling the effect of renal denervation on glucose homeostasis: more questions than answers?. Acta Diabetol. 61, 267\u2013280 (2024).","journal-title":"Acta Diabetol."},{"key":"2459_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05475-6","volume":"12","author":"AR Tzafriri","year":"2022","unstructured":"Tzafriri, A. R. et al. Morphometric analysis of the human common hepatic artery reveals a rich and accessible target for sympathetic liver denervation. Sci. Rep. 12, 1413 (2022).","journal-title":"Sci. Rep."},{"key":"2459_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cmet.2011.05.008","volume":"14","author":"R Rodriguez-Diaz","year":"2011","unstructured":"Rodriguez-Diaz, R. et al. Innervation patterns of autonomic axons in the human endocrine pancreas. Cell Metab. 14, 45\u201354 (2011).","journal-title":"Cell Metab."},{"key":"2459_CR16","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.jvir.2021.07.023","volume":"32","author":"T Pan","year":"2021","unstructured":"Pan, T. et al. Endovascular celiac denervation for glycemic control in patients with type 2 diabetes mellitus. J. Vasc. Inter. Radio. 32, 1519\u20131528.e1512 (2021).","journal-title":"J. Vasc. Inter. Radio."},{"key":"2459_CR17","unstructured":"Administration, U. S. F. a. D. Draft Guidance for Industry on Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention - Guidance Document (Federal Register, 2008)."},{"key":"2459_CR18","unstructured":"European Medicines Agency. Guideline on Clinical Investigation of Medicinal Products in the Treatment of Diabetes Mellitus (European Medicines Agency, 2018)."},{"key":"2459_CR19","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.2337\/db18-1209","volume":"68","author":"G Kraft","year":"2019","unstructured":"Kraft, G. et al. Sympathetic denervation of the common hepatic artery lessens glucose intolerance in the fat- and fructose-fed dog. Diabetes 68, 1143\u20131155 (2019).","journal-title":"Diabetes"},{"key":"2459_CR20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1177\/000456329803500107","volume":"35","author":"GT Ko","year":"1998","unstructured":"Ko, G. T. et al. The reproducibility and usefulness of the oral glucose tolerance test in screening for diabetes and other cardiovascular risk factors. Ann. Clin. Biochem. 35, 62\u201367 (1998).","journal-title":"Ann. Clin. Biochem."},{"key":"2459_CR21","doi-asserted-by":"publisher","first-page":"567","DOI":"10.14740\/jocmr2626e","volume":"8","author":"JA Benmoussa","year":"2016","unstructured":"Benmoussa, J. A., Clarke, M. & Bloomfield, D. White coat hyperglycemia: the forgotten syndrome. J. Clin. Med. Res. 8, 567\u2013568 (2016).","journal-title":"J. Clin. Med. Res."},{"key":"2459_CR22","doi-asserted-by":"publisher","first-page":"915482","DOI":"10.3389\/fendo.2022.915482","volume":"13","author":"K Guo","year":"2022","unstructured":"Guo, K. et al. Effect of the Chinese new year public holiday on the glycemic control of T1DM with intensive insulin therapy. Front. Endocrinol. 13, 915482 (2022).","journal-title":"Front. Endocrinol."},{"key":"2459_CR23","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.neuron.2023.12.012","volume":"112","author":"W Ren","year":"2024","unstructured":"Ren, W. et al. Sympathetic nerve-enteroendocrine L cell communication modulates GLP-1 release, brain glucose utilization, and cognitive function. Neuron 112, 972\u2013990.e978 (2024).","journal-title":"Neuron"},{"key":"2459_CR24","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","volume":"83","author":"V Vallon","year":"2021","unstructured":"Vallon, V. & Verma, S. Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annu. Rev. Physiol. 83, 503\u2013528 (2021).","journal-title":"Annu. Rev. Physiol."},{"key":"2459_CR25","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1038\/s41440-024-01816-2","volume":"47","author":"T Kusayama","year":"2024","unstructured":"Kusayama, T., Nagamori, Y., Takeuchi, K., Nakagawa, Y. & Takamura, M. Renal autonomic dynamics in hypertension: How can we evaluate sympathetic activity for renal denervation?. Hypertens. Res. 47, 2685\u20132692 (2024).","journal-title":"Hypertens. Res."},{"key":"2459_CR26","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/00004872-199917060-00001","volume":"17","author":"G Grassi","year":"1999","unstructured":"Grassi, G. & Esler, M. How to assess sympathetic activity in humans. J. Hypertens. 17, 719\u2013734 (1999).","journal-title":"J. Hypertens."},{"key":"2459_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40101-019-0193-2","volume":"38","author":"J Hayano","year":"2019","unstructured":"Hayano, J. & Yuda, E. Pitfalls of assessment of autonomic function by heart rate variability. J. Physiol. Anthropol. 38, 3 (2019).","journal-title":"J. Physiol. Anthropol."},{"key":"2459_CR28","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s42255-021-00408-5","volume":"3","author":"MG Myers Jr.","year":"2021","unstructured":"Myers, M. G. Jr., Affinati, A. H., Richardson, N. & Schwartz, M. W. Central nervous system regulation of organismal energy and glucose homeostasis. Nat. Metab. 3, 737\u2013750 (2021).","journal-title":"Nat. Metab."},{"key":"2459_CR29","doi-asserted-by":"crossref","unstructured":"Rousselle, S. D. et al. Neuromatous regeneration as a nerve response after catheter-based renal denervation therapy in a large animal model: immunohistochemical study. Circ. Cardiovasc. Interv. 8, e002293 (2015).","DOI":"10.1161\/CIRCINTERVENTIONS.114.002293"},{"key":"2459_CR30","doi-asserted-by":"publisher","first-page":"R806","DOI":"10.1152\/ajpregu.00227.2014","volume":"310","author":"K Rodionova","year":"2016","unstructured":"Rodionova, K. et al. Complex reinnervation pattern after unilateral renal denervation in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 310, R806\u2013R818 (2016).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"2459_CR31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1161\/HYPERTENSIONAHA.114.04176","volume":"65","author":"LC Booth","year":"2015","unstructured":"Booth, L. C. et al. Reinnervation of renal afferent and efferent nerves at 5.5 and 11 months after catheter-based radiofrequency renal denervation in sheep. Hypertension 65, 393\u2013400 (2015).","journal-title":"Hypertension"},{"key":"2459_CR32","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S0140-6736(13)62192-3","volume":"383","author":"H Krum","year":"2014","unstructured":"Krum, H. et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 383, 622\u2013629 (2014).","journal-title":"Lancet"},{"key":"2459_CR33","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/eurheartj\/ehac605","volume":"44","author":"A von Eckardstein","year":"2023","unstructured":"von Eckardstein, A., Nordestgaard, B. G., Remaley, A. T. & Catapano, A. L. High-density lipoprotein revisited: biological functions and clinical relevance. Eur. Heart J. 44, 1394\u20131407 (2023).","journal-title":"Eur. Heart J."},{"key":"2459_CR34","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/s41440-019-0233-7","volume":"42","author":"M Carlstr\u00f6m","year":"2019","unstructured":"Carlstr\u00f6m, M. & Braga, V. A. Mechanisms underlying the effects of renal denervation in renovascular hypertension. Hypertens. Res. 42, 754\u2013757 (2019).","journal-title":"Hypertens. Res."},{"key":"2459_CR35","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41440-022-01117-6","volume":"46","author":"H Nakagami","year":"2023","unstructured":"Nakagami, H. Mechanisms underlying the bidirectional association between nonalcoholic fatty liver disease and hypertension. Hypertens. Res. 46, 539\u2013541 (2023).","journal-title":"Hypertens. Res."},{"key":"2459_CR36","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1161\/HYP.0000000000000202","volume":"78","author":"ME Hall","year":"2021","unstructured":"Hall, M. E. et al. Weight-loss strategies for prevention and treatment of hypertension: a scientific statement from the American Heart Association. Hypertension 78, e38\u2013e50 (2021).","journal-title":"Hypertension"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02459-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02459-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02459-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T05:26:00Z","timestamp":1763011560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02459-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2459"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02459-6","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that the funding organization (Shanghai Golden Leaf Med Tech (Brattea) Co., Ltd.) had no role in the study design, data collection, analysis, interpretation, or writing of the report. The authors declare no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"371"}}